<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761982</url>
  </required_header>
  <id_info>
    <org_study_id>OVISEV-01</org_study_id>
    <nct_id>NCT00761982</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment.</brief_title>
  <official_title>Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Central de Asturias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Central de Asturias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the safety and efficacy on an autologous CD34+ subset&#xD;
      bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered&#xD;
      acute middle cerebral artery stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed trial will involve the recruitment of a total of 20 patients.&#xD;
&#xD;
      The cells will be collected from ten subject recruited as cases, via bone marrow sampling.&#xD;
      The aspirate will be centrifuged on a Ficoll density gradient to isolate mononuclear cells,&#xD;
      which will be resuspended in heparinized isotonic saline for infusion into the area of the&#xD;
      stroke intra-arterially using the middle cerebral artery.&#xD;
&#xD;
      The investigators will monitor each case and control for a period of 6 months post-stem cell&#xD;
      infusion. Initially, they will be subjected to a review after one month,three months and&#xD;
      finally 6 months.&#xD;
&#xD;
      Assessment of adverse events will be by physical examination and measurement of laboratory&#xD;
      parameters. Assessment of efficacy will be by physical examination and the measurement of&#xD;
      laboratory, CT and MRI parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of new neurological deficits and adverse effects during the timeframe.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in clinical function as assessed by the Modified Rankin Score, Barthel Scale and NIH stroke scale.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Infarction, Middle Cerebral Artery</condition>
  <arm_group>
    <arm_group_label>bone marrow stem cells</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Procedure: Infusion of autologous CD34+ stem cells into middle cerebral artery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infusion on autologous CD34+ stem cells into middle cerebral artery</intervention_name>
    <description>Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients</description>
    <arm_group_label>bone marrow stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptoms and signs of clinically definite middle cerebral artery acute stroke.&#xD;
&#xD;
          -  Time of stroke onset is known and treatment can be started between day 5 and 9 of&#xD;
             onset.&#xD;
&#xD;
          -  DWI-MRI has reliably shown relevant acute ischemic lesions&#xD;
&#xD;
          -  Extracranial duplex/transcranial Doppler must confirm intra/extracranial arteries&#xD;
             permeability.&#xD;
&#xD;
          -  The stroke is severe (NIH Stroke Scale &gt;= 8 before procedure).&#xD;
&#xD;
          -  An age range of 18-80 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients out of inclusion age range.&#xD;
&#xD;
          -  Lacunar infarction.&#xD;
&#xD;
          -  Patients with cancer.&#xD;
&#xD;
          -  Patients with present or previous malignant disease during the last 5 years, except&#xD;
             for basal cell carcinoma.&#xD;
&#xD;
          -  Hematological causes of stroke.&#xD;
&#xD;
          -  Severe co-morbidity.&#xD;
&#xD;
          -  Hepatic or renal dysfunction.&#xD;
&#xD;
          -  The patient is female and of childbearing potential (unless it is certain that&#xD;
             pregnancy is not possible) or breast feeding.&#xD;
&#xD;
          -  Patient is likely to be unavailable for follow-up.&#xD;
&#xD;
          -  Patient with evidence of life threatening infection of life threatening illness.&#xD;
&#xD;
          -  Patient was already dependent in activities of daily living before the present acute&#xD;
             stroke.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospitales Universitarios Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>September 28, 2008</study_first_submitted>
  <study_first_submitted_qc>September 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <last_update_submitted>November 27, 2011</last_update_submitted>
  <last_update_submitted_qc>November 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Infarction, Middle Cerebral Artery</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

